These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 11600398)

  • 1. In vitro and in vivo activities of sitafloxacin against Chlamydia spp.
    Miyashita N; Niki Y; Matsushima T
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3270-2. PubMed ID: 11600398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
    Miyashita N; Niki Y; Kishimoto T; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
    Niki Y; Miyashita N; Kubota Y; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Apr; 41(4):857-9. PubMed ID: 9087506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Infect Chemother; 2002 Mar; 8(1):115-7. PubMed ID: 11957133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
    Kimura M; Kishimoto T; Niki Y; Soejima R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):801-3. PubMed ID: 8494377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
    Roblin PM; Montalban G; Hammerschlag MR
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1402-3. PubMed ID: 8092845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in-vitro activity of levofloxacin against Chlamydia spp.
    Donati M; Rumpianesi F; Marchetti F; Sambri V; Cevenini R
    J Antimicrob Chemother; 1998 Nov; 42(5):670-1. PubMed ID: 9848456
    [No Abstract]   [Full Text] [Related]  

  • 8. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.
    Soejima R; Niki Y; Kishomoto T; Kimura M; Kubota Y
    Drugs; 1995; 49 Suppl 2():257-9. PubMed ID: 8549323
    [No Abstract]   [Full Text] [Related]  

  • 9. Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.
    Nakata K; Okazaki Y; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1757-62. PubMed ID: 7986006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.
    Nakata K; Maeda H; Fujii A; Arakawa S; Umezu K; Kamidono S
    Antimicrob Agents Chemother; 1992 Jan; 36(1):188-90. PubMed ID: 1317145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potent antibacterial activity of Sitafloxacin against fluoroquinolone-resistant clinical isolates of Vibrio cholerae O1.
    Okuda J; Ramamurthy T; Yamasaki S
    Microbiol Immunol; 2007; 51(4):467-9. PubMed ID: 17446687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
    Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
    Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
    Dhople AM; Namba K
    J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.
    Roblin PM; Hammerschlag MR
    J Antimicrob Chemother; 1999 Oct; 44(4):549-51. PubMed ID: 10588319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.
    Smith RP; Baltch AL; Ritz WJ; Carpenter AN; Halse TA; Bopp LH
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2081-4. PubMed ID: 15155203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.
    Yamamoto N; Fujita J; Shinzato T; Higa F; Tateyama M; Tohyama M; Nakasone I; Yamane N
    Int J Antimicrob Agents; 2006 Feb; 27(2):171-3. PubMed ID: 16417990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
    Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
    Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.
    Dhople AM; Namba K
    J Antimicrob Chemother; 2002 Nov; 50(5):727-9. PubMed ID: 12407131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
    Hammerschlag MR; Roblin PM
    J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro activities of doxycycline and enrofloxacin against European Chlamydia psittaci strains from turkeys.
    Butaye P; Ducatelle R; De Backer P; Vermeersch H; Remon JP; Haesebrouck F
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2800-1. PubMed ID: 9420065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.